Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.5% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals Inc (AMLX) is a healthcare company listed on the NASDAQ stock exchange. The company focuses on developing therapies for neurodegenerative diseases.

Why is Amylyx Pharmaceuticals going down?

AMLX stock is down 5.5% on Mar 30, 2026 19:01

• The bearish movement in AMLX's stock price today can be attributed to a realignment of holdings by a major investment firm, resulting in the firm reporting 0% beneficial ownership of AMLX common stock. This change may have caused uncertainty among investors, leading to a sell-off of the stock.
• Despite analysts on Wall Street maintaining a bullish sentiment on AMLX and reiterating Buy ratings with optimistic price targets, the sudden change in the investment firm's ownership status likely overshadowed these positive recommendations.
• Additionally, the discontinuation of the ORION program for AMX0035, as highlighted in recent SEC filings, could have raised concerns among investors about the company's future pipeline and potential revenue streams, contributing to the bearish market movement.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Vanguard realigns holdings; AMLX ownership reported at 0% (Vanguard)

The Vanguard Group has filed an amendment to its Schedule 13G/A, reporting 0% beneficial ownership of Amylyx Pharmaceuticals Inc (AMLX) common stock following an internal realignment on January 12, 2026. This realignment means certain subsidiaries will now report their holdings separately, resulting in Vanguard no longer being deemed to beneficially own those securities. The filing explicitly states Vanguard holds 0 shares of Amylyx common stock.

https://www.stocktitan.net/sec-filings/AMLX/schedule-13g-a-amylyx-pharmaceuticals-inc-amended-passive-investment--ab79672002fb.html

Wall Street Analysts Are Bullish on Top Healthcare Picks

Wall Street analysts are showing bullish sentiment towards two healthcare companies: Amylyx Pharmaceuticals Inc (AMLX) and Rubicon Organics (ROMJF). An analyst from LifeSci Capital maintained a Buy rating on Amylyx with a $24.00 price target, while a Haywood analyst maintained a Buy rating on Rubicon Organics with a C$1.30 price target. Both companies have received generally positive consensus ratings from analysts, indicating potential upside.

https://www.theglobeandmail.com/investing/markets/stocks/AMLX-Q/pressreleases/950824/wall-street-analysts-are-bullish-on-top-healthcare-picks/

AMLX SEC Filings - Amylyx Pharmaceuticals 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Amylyx Pharmaceuticals (AMLX) SEC filings, including annual reports, quarterly earnings, and material event disclosures. It highlights key recent 8-K filings affecting the company's financial condition and R&D programs, and also features recent insider transactions and institutional ownership updates. The platform aims to aid investors and traders by offering AI-powered summaries of these regulatory documents.

https://www.stocktitan.net/sec-filings/AMLX/page-3.html

AMLX SEC Filings - Amylyx Pharmaceuticals 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Amylyx Pharmaceuticals (AMLX) SEC filings, offering access to official regulatory documents like 10-K, 10-Q, and 8-K forms. It highlights key events covered in recent 8-K filings, such as financial results, public offerings, and R&D updates including the discontinuation of the ORION program for AMX0035. The platform also offers AI-powered summaries to quickly extract important information from these filings and tracks significant institutional ownership changes.

https://www.stocktitan.net/sec-filings/AMLX/page-7.html

HC Wainwright Reaffirms Buy Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX)

HC Wainwright has reissued a "Buy" rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) with a $34 price target, indicating a potential upside of approximately 148.9% from its current price. Other analysts also generally hold a "Moderate Buy" consensus with an average price target of $20.11. The company recently reported quarterly earnings that beat analysts' estimates, and despite some insider selling, institutional investors have been adjusting their positions in the stock.

https://www.marketbeat.com/instant-alerts/hc-wainwright-reaffirms-buy-rating-for-amylyx-pharmaceuticals-nasdaqamlx-2026-03-25/

Trending Today

Wingstop Inc. ($WING) Stock Forecast: Down 5.7% Today

Corning Incorporated ($GLW) Stock Forecast: Up 5.5% Today

Parker-Hannifin Corporation ($PH) Stock Forecast: Up 5.0% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Up 6.0% Today

Lamb Weston Holdings Inc. ($LW) Stock Forecast: Down 5.2% Today

Keysight Technologies Inc. ($KEYS) Stock Forecast: Up 5.0% Today

Intel Corporation ($INTC) Stock Forecast: Up 11.0% Today

Centene Corporation ($CNC) Stock Forecast: Up 5.7% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Up 5.2% Today

Aptiv PLC ($APTV) Stock Forecast: Down 10.1% Today

Amylyx Pharmaceuticals Price History

26.01.2026 - AMLX Stock was up 5.4%

• The positive market performance of Amylyx Pharmaceuticals could be attributed to the optimistic outlook and anticipation surrounding the forthcoming financial results disclosure.
• FDA's contentious approval of the ALS drug, Relyvrio, and the challenges faced by Biogen and Ionis Pharmaceuticals in halting their ALS drug, BIIB105, may have created a conducive environment for companies like Amylyx Pharmaceuticals in the ALS treatment sector.
• Investors may be hopeful about Amylyx's prospects in the ALS market, given the pressing need for effective treatments and recent industry advancements.
• The favorable response from the market to Amylyx Pharmaceuticals could also be influenced by the company's strategic positioning and growth prospects in the field of neurodegenerative disease treatment.

12.02.2026 - AMLX Stock was down 6.5%

• The decline in AMLX stock could be connected to investors potentially feeling unimpressed by the disclosures made at a recent conference concerning the avexitide program and the company's overall pipeline expansion.
• Despite the encouraging news of the Phase 3 trial nearing completion and the forthcoming Q3 data release, market expectations may have been higher for significant advancements or milestones.
• The absence of immediate positive triggers or groundbreaking updates might have prompted traders to take profits, as they may have been anticipating a more notable market response to the company's advancements.
• Investors may be taking a profit-making strategy following the conference updates, leading to a temporary downturn in the stock price.

24.01.2026 - AMLX Stock was up 6.0%

• AMLX experienced a strong bullish movement likely due to the FDA approval of Relyvrio, a new ALS drug, despite controversies surrounding its preliminary trial data. This approval signifies potential growth opportunities for AMLX in the ALS treatment market.
• The decision by Biogen and Ionis Pharmaceuticals to shelve their ALS drug development after a study failure could have further boosted investor confidence in AMLX as it positions itself favorably in the competitive landscape.
• The setbacks in ALS drug development faced by other companies highlight the challenges in the industry, making AMLX a potentially attractive investment option for traders seeking growth in the pharmaceutical sector.

03.02.2026 - AMLX Stock was down 8.0%

• Today's bearish movement in AMLX's stock price could be attributed to the significant financial declines reported in fiscal year 2024, with revenue dropping by 77.1% and net income at a negative value.
• Insider selling activities, including a plan to sell a substantial number of shares, might have raised concerns among investors about the company's future prospects.
• Participation in upcoming investor conferences could potentially provide a platform for the company to showcase its developments, but the mixed financial signals and insider selling could have overshadowed any positive sentiment, leading to the bearish market movement.
• The automatic sale of shares by the Chief Legal Officer for tax purposes further added to the selling pressure on the stock, contributing to the overall bearish sentiment surrounding AMLX today.

10.02.2026 - AMLX Stock was up 7.7%

• The uptrend in AMLX stock today is linked to the favorable Q4 2025 earnings release that exceeded EPS projections and highlighted significant advancements in the company's pipeline.
• The Co-CEOs' sale of shares to address tax obligations, though initially raising questions, was clarified as obligatory transactions tied to RSU vesting, demonstrating confidence in the company's future outlook.
• Amylyx Pharmaceuticals' reduced net losses and the initiation of new shelf registrations have bolstered the company's financial flexibility, despite the potential for shareholder dilution, positively shaping the stock's investment story.

30.02.2026 - AMLX Stock was down 5.5%

• The bearish movement in AMLX's stock price today can be attributed to a realignment of holdings by a major investment firm, resulting in the firm reporting 0% beneficial ownership of AMLX common stock. This change may have caused uncertainty among investors, leading to a sell-off of the stock.
• Despite analysts on Wall Street maintaining a bullish sentiment on AMLX and reiterating Buy ratings with optimistic price targets, the sudden change in the investment firm's ownership status likely overshadowed these positive recommendations.
• Additionally, the discontinuation of the ORION program for AMX0035, as highlighted in recent SEC filings, could have raised concerns among investors about the company's future pipeline and potential revenue streams, contributing to the bearish market movement.

04.02.2026 - AMLX Stock was up 5.5%

• AMLX reported significantly reduced losses in 2025, with a pivot towards advancing their avexitide program for post-bariatric hypoglycemia (PBH) showing promising results.
• The completion of recruitment for the pivotal Phase 3 LUCIDITY trial and the selection of new development candidates indicate positive progress in their pipeline, boosting investor confidence.
• Despite an insider, Joshua B. Cohen, planning to sell shares, the overall positive financial results and strategic advancements seem to have outweighed any potential concerns, driving the bullish market movement for AMLX today.

25.02.2026 - AMLX Stock was up 5.4%

• An investment firm maintains a "Buy" rating for AMLX with a high price target, suggesting a notable potential for growth and enhancing investor confidence.
• The conclusion of enrollment in the crucial Phase 3 LUCIDITY clinical trial for avexitide in post-bariatric hypoglycemia (PBH) demonstrates advancement in a promising treatment, garnering positive attention in the market.
• Amylyx's updated corporate presentation outlining Phase 3 trial progress and strong financial standing, with funds available until 2028, has further encouraged investors.
• The successful completion of patient enrollment in the Phase 3 LUCIDITY trial, alongside positive updates on other research endeavors and a solid financial position, has solidified the market's positive outlook on Amylyx Pharmaceuticals.

27.01.2026 - AMLX Stock was up 5.4%

• Amylyx Pharmaceuticals' stock (AMLX) experienced a bullish movement due to its participation in upcoming investor conferences and potential positive outcomes from its pipeline therapies.
• The Chief Legal Officer, Gina Mazzariello, sold shares, but this did not impact investors significantly, with several analysts increasing their valuation estimates for AMLX, showing faith in the company's pipeline.
• The forthcoming announcement of financial results on March 3, 2026, added to the positive outlook on AMLX, with investors awaiting insights into the company's performance and future prospects.
• Although concerns were voiced by TipRanks' AI Analyst, Spark, about financial performance and technicals, overall market sentiment towards Amylyx Pharmaceuticals remained positive, leading to the uptrend in the stock price.

05.02.2026 - AMLX Stock was down 5.9%

• The bearish movement in AMLX today may have been influenced by the Co-CEOs selling shares to cover tax obligations related to the vesting of restricted stock units, sparking concerns about leadership confidence.
• Despite surpassing EPS expectations and showcasing progress in the pipeline with positive Q4 and full-year 2025 earnings, the impact of Co-CEOs' share sales may have outweighed the optimistic results.
• An adverse reaction from investors towards insider selling, despite the company's robust financial standing, ample cash reserves, and advancements in its drug programs.
• The market's response could also be attributed to short-term profit-taking by investors post-recent positive developments, leading to a temporary decline in the stock price.

24.02.2026 - AMLX Stock was down 6.1%

• The completion of enrollment in the pivotal Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia (PBH) did not seem to positively impact AMLX's stock performance.
• Despite the positive developments in the clinical trials and the strong cash position of $317 million providing a financial runway into 2028, investors may have had concerns about the company's overall financial performance.
• The market reaction could be attributed to profit-taking by investors who were expecting a more immediate positive impact on the stock price following the enrollment completion and positive trial updates.
• It's possible that the market sentiment was influenced by external factors or broader industry trends affecting biopharmaceutical companies rather than specific news related to Amylyx Pharmaceuticals.

23.02.2026 - AMLX Stock was up 1.6%

• A surge in the price target and a "buy" rating by Guggenheim analyst, alongside optimistic projections from other analysts, likely boosted the stock's performance.
• Notable investment by Maven Securities LTD in AMLX and increased institutional involvement suggest mounting confidence in the company's future.
• The narrowing of losses, expanded shelf capacity, and strategic focus on advancing its pipeline at Amylyx Pharmaceuticals have likely reassured investors and garnered favorable attention, leading to the upward momentum in the stock price.